Multidisciplinary Cancer Teams Lack Information on Patients' Comborbidity
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers in New Zealand have found that multidisciplinary cancer team meetings need to systematically consider treatment of patients with comorbidity in order to improve outcomes of patients with cancer with comorbidities.
For the study, researchers sought to investigate how comorbidity of patients with cancer is considered in multidisciplinary cancer team meetings, and how information on comorbidity impacts decision-making. Researchers conducted a systematic literature review to evaluate previous research on consideration and impact of comorbidity in multidisciplinary cancer team decision-making of their patients' treatments. They identified 21 studies for the review.
Results showed that lack of information on patients' comorbidity in team meetings affect the ability of team members to make therapy recommendations and decreases the likelihood that those recommendations are implemented in patients with comorbidity.
In addition, researchers found that when treatment for those with comorbidity is different than from what is recommended, it is more conservative even though the recommended treatment may be effective and tolerated. Researchers also found that team members are likely unaware that they are ignoring comborbidity issues.
The authors conclude that multidisciplinary team members should systematically consider treatment options for patients with cancer and comorbidity in order to enhance decision-making.
Multidisciplinary cancer team meetings need to systematically consider treatment of patients with comorbidity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk